The pharmaceutical industry is constantly striving for innovative ways to bridge the translational gap between preclinical and clinical drug development to reduce attrition. Substantial effort has focused on the preclinical application of human-based microphysiological systems (MPS) to better identify compounds not likely to be safe or efficacious in the clinic. The Coronavirus 2019 (COVID-19) pandemic provides a clear opportunity for assessing the utility of MPS models of the lungs and other organ systems affected by the disease in understanding the pathophysiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in the development of effective therapeutics. Here, we review progress and describe the establishment of a global working group to coordinate activities around MPS and COVID-19 and to maximize their scientific, human health, and animal welfare impacts.

制药行业一直在努力寻找创新方法来弥合临床前和临床药物开发之间的转化差距，以减少人员流失。大量的努力集中在以人为基础的微生理系统 (MPS) 的临床前应用，以更好地识别在临床上不太可能安全或有效的化合物。2019 年冠状病毒 (COVID-19) 大流行为评估肺部和其他受该疾病影响的器官系统的 MPS 模型在了解严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 和在开发有效的治疗方法。在这里，我们回顾了进展并描述了全球工作组的建立，以协调围绕 MPS 和 COVID-19 的活动，并最大限度地发挥其科学、